Avalo Therapeutics, Inc. (AVTX)
19.23
+0.23
(+1.21%)
USD |
NASDAQ |
Sep 04, 16:00
19.24
+0.01
(+0.05%)
After-Hours: 20:00
Avalo Therapeutics SG&A Expense (TTM) : 27.06M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.06M |
| March 31, 2026 | 24.21M |
| December 31, 2025 | 22.90M |
| September 30, 2025 | 21.60M |
| June 30, 2025 | 20.31M |
| March 31, 2025 | 19.59M |
| December 31, 2024 | 17.24M |
| September 30, 2024 | 14.68M |
| June 30, 2024 | 12.89M |
| March 31, 2024 | 10.79M |
| December 31, 2023 | 10.30M |
| September 30, 2023 | 10.58M |
| June 30, 2023 | 11.38M |
| March 31, 2023 | 11.74M |
| December 31, 2022 | 20.71M |
| September 30, 2022 | 23.73M |
| June 30, 2022 | 26.38M |
| March 31, 2022 | 31.00M |
| December 31, 2021 | 24.66M |
| September 30, 2021 | 23.29M |
| June 30, 2021 | 22.40M |
| March 31, 2021 | 21.75M |
| December 31, 2020 | 19.76M |
| September 30, 2020 | 17.99M |
| Date | Value |
|---|---|
| June 30, 2020 | 15.63M |
| March 31, 2020 | 11.94M |
| September 30, 2019 | 14.07M |
| June 30, 2019 | 15.41M |
| March 31, 2019 | 17.83M |
| December 31, 2018 | 19.20M |
| September 30, 2018 | 17.72M |
| June 30, 2018 | 15.67M |
| March 31, 2018 | 12.03M |
| December 31, 2017 | 8.915M |
| September 30, 2017 | 6.016M |
| June 30, 2017 | 5.568M |
| March 31, 2017 | 5.765M |
| December 31, 2016 | 7.084M |
| September 30, 2016 | 7.913M |
| June 30, 2016 | 6.932M |
| March 31, 2016 | 6.056M |
| December 31, 2015 | 4.167M |
| September 30, 2015 | 3.038M |
| June 30, 2015 | 3.195M |
| March 31, 2015 | 2.434M |
| June 30, 2014 | 1.674M |
| March 31, 2014 | 0.8791M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Incyte Corp. | 1.399B |
| AbbVie, Inc. | 14.67B |
| Rezolute, Inc. | 27.48M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |